• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NanoVibronix Announces Pricing of $10 Million Public Offering of Preferred Stock and Warrants

    5/15/25 9:00:00 AM ET
    $NAOV
    Industrial Specialties
    Health Care
    Get the next $NAOV alert in real time by email

    NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the pricing of an underwritten public offering of approximately 400,000 shares of the Company's Series G Convertible Preferred Stock ("Preferred Stock"), par value $0.001 per share and Warrants to purchase up to 4,901,961 shares of common stock, par value $0.001 per share (the "Common Stock") of the Company at an exercise price of $2.04 per share (the "Warrants"). The combined public offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00. The closing of the public offering is expected to occur on or about May 19, 2025, subject to the satisfaction of customary closing conditions.

    Dawson James Securities, Inc. is acting as the sole bookrunning manager for the public offering.

    The gross proceeds of the public offering are expected to be approximately $10 million before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for (i) the redemption of the principal amount of its outstanding debenture with an aggregate principal amount of $1,300,000, initially issued on February 14, 2025, pursuant to the terms and conditions of such debenture and up to $700,000 to be applied to the partial repayment of an outstanding note issued on January 17, 2025, in the aggregate principal amount of $2,497,308 and (ii) general corporate purposes.

    This public offering is being made by the Company pursuant to a registration statement on Form S-1 (File No. 333-284973), as amended, originally filed on February 14, 2025, and declared effective by the U.S. Securities and Exchange Commission ("SEC") on May 14, 2025. The securities may only be offered by means of a prospectus which forms a part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC and a final prospectus relating to the offering will be filed with the SEC. Copies of the final prospectus may be obtained, when available, at the SEC's website at www.sec.gov or from Dawson James Securities, Inc. Attention: Prospectus Department, 101 North Federal Highway, Suite 600, Boca Raton, FL 33432, [email protected] or toll free at 866.928.0928.

    This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

    About NanoVibronix, Inc.

    NanoVibronix, Inc. (NASDAQ:NAOV), is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Nesher, Israel, the company focuses on two distinct technology platforms:

    • Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. This technology is designed for use in a variety of medical applications, including the disruption of biofilms and bacterial colonization, as well as the treatment of pain. These devices are intended for use in home or care settings without the need for continuous professional supervision.
    • ENvue™ Navigation Platform, developed and operated by ENvue Medical, with offices in Arlington Heights, Illinois and Tel Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue offers real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.

    NanoVibronix / ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.

    Forward-looking Statements

    This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. These forward-looking statements include, but are not limited to: statements regarding the completion of the offering, the satisfaction of closing conditions, the use of proceeds from the offering, and future expectations and plans and prospects for the Company. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of the Company's existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of the Company's products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) the Company's limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for the Company's products; (ix) the Company's ability to successfully obtain and maintain intellectual property protection covering the Company's products; (x) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) the Company's reliance on single suppliers for certain product components, (xii) the need to raise additional capital to meet the Company's future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiii) the Company's conducting business in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge on the SEC's web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250515253302/en/

    Brett Maas, Managing Principal, Hayden IR, LLC

    [email protected]

    (646) 536-7331

    Get the next $NAOV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $NAOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAOV
    SEC Filings

    See more
    • SEC Form DEFA14A filed by NanoVibronix Inc.

      DEFA14A - NanoVibronix, Inc. (0001326706) (Filer)

      6/25/25 4:05:18 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form DEF 14A filed by NanoVibronix Inc.

      DEF 14A - NanoVibronix, Inc. (0001326706) (Filer)

      6/20/25 8:00:09 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form PRE 14A filed by NanoVibronix Inc.

      PRE 14A - NanoVibronix, Inc. (0001326706) (Filer)

      6/9/25 5:13:23 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Murphy Brian M

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/3/25 4:05:16 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Mika Thomas

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:26:30 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Brown Stephen Russell

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:25:07 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Financials

    Live finance-specific insights

    See more
    • NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

      NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh

      9/14/22 9:25:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NanoVibronix's ENvue Medical Division Announces Agreement with New York Medical Center to Implement ENvue™ Navigation Systems for Enteral Feeding Tube Placement

      Dual-System Agreement Highlights Transition Towards Advanced Bedside Navigation NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in non-invasive therapeutic devices, announced today that a regional acute care hospital in upstate New York has signed an agreement to acquire two ENvue™ Navigation Systems through its ENvue Medical division ("ENvue" or "ENvue Medical"). The systems, which are currently expected to be delivered in the third quarter of 2025, will support bedside placement of nasoenteric feeding tubes in adult patients. ENvue's electromagnetic technology provides clinicians with real-time visualization of tube directi

      6/24/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • ENvue Medical Granted U.S. Patent for Pediatric Feeding Tube Guidance System

      Patent strengthens ENvue's IP position as it advances toward pediatric regulatory clearance and expanded clinical use NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, announced today, through its ENvue Medical Holdings LLC division ("ENvue Medical" or "ENvue"), a new U.S. patent for its pediatric feeding tube guidance system. U.S. Patent No. 12,324,632, titled "Insertion Device Positioning Guidance System," further strengthens ENvue Medical's intellectual property portfolio and reflects the Company's ongoing commitment to innovation in feeding tube placement technologies. This newly granted patent cover

      6/11/25 8:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Announces CEO Transition

      NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

      6/4/25 8:38:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Leadership Updates

    Live Leadership Updates

    See more
    • NanoVibronix Announces CEO Transition

      NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the retirement of Brian Murphy as Chief Executive Officer, effective immediately. The Company's Board of Directors has appointed Doron Besser, CEO of ENvue Medical Holdings, LLC ("ENvue"), a wholly-owned subsidiary of the Company, as NanoVibronix's new CEO, also effective immediately. Mr. Murphy will remain on the Company's Board of Directors as a director. His continued service will support governance continuity at the Board level. As previously announced, on February 14, 2025, the Company consummated and completed its acquisition of ENvue,

      6/4/25 8:38:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

      NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on

      12/15/22 4:05:00 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Reports First Quarter 2022 Financial Results

      Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr

      5/17/22 8:30:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      11/14/24 5:17:34 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by NanoVibronix Inc.

      SC 13G - NanoVibronix, Inc. (0001326706) (Subject)

      2/14/24 3:45:41 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      2/16/21 3:49:24 PM ET
      $NAOV
      Industrial Specialties
      Health Care